(Q34017627)

30 July 2017

1 reference

title

Transdermal delivery of drugs for the treatment of bone diseases (English)

1 reference

30 July 2017

Ramachandran C

1

1 reference

PubMed ID

10963836

30 July 2017

Fleisher D

series ordinal

2

1 reference

PubMed ID

10963836

30 July 2017

language of work or name

English

0 references

publication date

1 August 2000

1 reference

Advanced Drug Delivery Reviews

30 July 2017

1 reference

30 July 2017

42

1 reference

30 July 2017

3

1 reference

30 July 2017

197-223

1 reference

Risk factors for falls as a cause of hip fracture in women. The Northeast Hip Fracture Study Group

30 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

The worldwide problem of osteoporosis: insights afforded by epidemiology

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

Fall severity and bone mineral density as risk factors for hip fracture in ambulatory elderly

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

Long-term fracture prediction by bone mineral assessed at different skeletal sites

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

The diagnosis of osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

Involutional osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

World-wide projections for hip fracture

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

Secular trends in the incidence of hip fractures

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

The direct medical costs of osteoporosis for American women aged 45 and older, 1986.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

Prevalence of low femoral bone density in older U.S. women from NHANES III

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

Consensus development conference: prophylaxis and treatment of osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

Reduced mortality associated with long-term postmenopausal estrogen therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

Estrogen and cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

Reduction of cardiovascular disease-related mortality among postmenopausal women who use hormones: evidence from a national cohort

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

Mortality in a cohort of long-term users of hormone replacement therapy: an updated analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

Estrogen use and cardiovascular disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

Estrogen replacement therapy and protection from acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

Decreased mortality in users of estrogen replacement therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

Menopausal Estrogen Replacement Therapy and Breast Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

The Use of Estrogens and Progestins and the Risk of Breast Cancer in Postmenopausal Women

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

Pharmacology and pharmacokinetics of estrogens

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

Pharmacokinetic and pharmacologic variation between different estrogen products

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

Comparative metabolic study of percutaneous versus oral micronized 17 beta-oestradiol in replacement therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

Transdermal estradiol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of menopausal complaints

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

Biological effects of estradiol-17 beta in postmenopausal women: oral versus percutaneous administration

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

Biologic effects of transdermal estradiol

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

Mechanism of percutaneous absorption. II. Transient diffusion and the relative importance of various routes of skin penetration

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

Lipids and the epidermal permeability barrier

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

Epidermal lipids, barrier function, and desquamation

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

Skin lipids: an update

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

Transfollicular drug delivery

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

Propionate-caprylate mixtures in the treatment of dermatomycoses, with a review of fatty acid therapy in general

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

Determination of density of follicles on various regions of the face by cyanoacrylate biopsy: correlation with sebum output

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

Factors accelerating the penetration of histamine through normal intact human skin

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

Regional variation in percutaneous penetration of 14C cortisol in man

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

Regional variation in percutaneous penetration in man. Pesticides.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

In vitro percutaneous absorption in mouse skin: Influence of skin appendages

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

Skin permeability in vivo: comparison in rat, rabbit, pig and man

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

In vivo correlation between stratum corneum reservoir function and percutaneous absorption

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

In vivo relationship between horny layer reservoir effect and percutaneous absorption in human and rat

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

The measurement of the stratum corneum reservoir. A predictive method for in vivo percutaneous absorption studies: influence of application time

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

Regional variation in percutaneous absorption in man: measurement by the stripping method

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

Skin reservoir formation and bioavailability of dermally administered chemicals in hairless guinea pigs

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

Skin aging. Effect on transepidermal water loss, stratum corneum hydration, skin surface pH, and casual sebum content

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

In vivo relationship between transepidermal water loss and percutaneous penetration of some organic compounds in man: effect of anatomic site

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

Percutaneous Penetration of Methyl Nicotinate at Three Anatomic Sites: Evidence for an Appendageal Contribution to Transport?

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

In vivo human skin barrier modulation by topical application of fatty acids

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

Effect of sodium lauryl sulfate-induced skin irritation on in vivo percutaneous penetration of four drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

Effect of sodium lauryl sulfate (SLS) on in vitro percutaneous penetration of water, hydrocortisone and nickel

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

Contributions of drug solubilization, partitioning, barrier disruption, and solvent permeation to the enhancement of skin permeation of various compounds with fatty acids and amines

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

Influence of nonionic liposomal composition on topical delivery of peptide drugs into pilosebaceous units: an in vivo study using the hamster ear model

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

Evaluation of the hairless rat as a model for in vivo percutaneous absorption

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

Technique for preparing appendage-free skin (Scar) on hairless mouse

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

Follicles play an important role in percutaneous absorption

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

Estradiol distribution and penetration in rat skin after topical application, studied by high resolution autoradiography

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

Menorest: technical development and pharmacokinetic profile

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

Pharmacokinetics and pharmacodynamics of transdermal dosage forms of 17β-estradiol: Comparison with conventional oral estrogens used for hormone replacement

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

Absorption and bioavailability of oestradiol from a gel, a patch and a tablet.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

Comparative bioavailability study of an once-a-week matrix versus a twice-a-week reservoir transdermal estradiol delivery systems in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

Plasma estradiol concentrations and pharmacokinetics following transdermal application of Menorest 50 or Systen (Evorel) 50.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

Bioavailability Study of Menorest®, a New Estrogen Transdermal Delivery System, Compared with a Transdermal Reservoir System.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

Bioavailability of estradiol from a new matrix and a conventional reservoir-type transdermal therapeutic system

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

Comparison of transdermal to oral estradiol administration on hormonal and hepatic parameters in women with premature ovarian failure

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

Transdermally administered oestradiol combined with oral medroxyprogesterone acetate: the effects on lipoprotein metabolism in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

Comparison of the impact of oral versus transdermal estrogen on serum lipoproteins

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

Long-term estrogen replacement therapy prevents bone loss and fractures

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

Long-term prevention of postmenopausal osteoporosis by oestrogen. Evidence for an increased bone mass after delayed onset of oestrogen treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

Postmenopausal hormone therapy and mortality.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

Effect of 10 years' hormone replacement therapy on bone mineral content in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

Low and conventional dose transdermal oestradiol are equally effective at preventing bone loss in spine and femur at all post-menopausal ages.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

Preventive effects of transdermal 17 beta-estradiol on osteoporotic changes after surgical menopause: a two-year placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

Long-term effects of percutaneous estradiol on bone loss and bone metabolism in postmenopausal hysterectomized women

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

A dose-ranging trial of a matrix transdermal 17beta-estradiol for the prevention of bone loss in early postmenopausal women. International Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

Matrix delivery transdermal 17beta-estradiol for the prevention of bone loss in postmenopausal women. The International Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

Transdermal estradiol overall safety profile

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

Efficacy and safety of Menorest in two positive-controlled studies.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

Efficacy and tolerability of Estraderm MX, a new estradiol matrix patch

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

Bisphosphonates: a review of their pharmacokinetic properties

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

Bisphosphonates: from the laboratory to the clinic and back again

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

An open-label extension study of alendronate treatment in elderly women with osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

Efficacy and safety of drugs for Paget's disease of bone

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

Treatment of Paget's disease of bone with alendronate

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

Bisphosphonates as anticancer drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

Bisphosphonates act on rat bone resorption through the mediation of osteoblasts

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

Focal osteomalacia due to low-dose diphosphonate therapy in Paget's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

Mineralisation defects with pamidronate therapy for Paget's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

Esophagitis associated with the use of alendronate

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

Pamidronate: an unrecognized problem in gastrointestinal tolerability

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

Risedronate in the treatment of Paget's disease of bone: an open label, multicenter study.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

On the absorption of alendronate in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

Transdermal penetration enhancers: applications, limitations, and potential.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

Enhanced skin permeation of sex hormones with novel topical spray vehicles.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

Transdermal delivery of estradiol in postmenopausal women with a novel topical aerosol

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

Reconstruction of the formative site in iliac trabecular bone in 20 normal individuals employing a kinetic model for matrix and mineral apposition

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

Clinical pharmacology of alendronate sodium

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

Cutaneous and parenteral studies with vehicles containing isopropyl myristate and peanut oil

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

Investigations on the percutaneous absorption of the antidepressant rolipram in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900062-4

7 January 2021

10.1016/S0169-409X(00)00062-4

Identifiers

DOI

1 reference

30 July 2017

1 reference

PubMed ID

10963836